RedHill Biopharma Ltd. Acquires Exclusive Rights to a MAP Bacterium Companion Diagnostic Test for its RHB-104 (Crohn’s) Drug  
9/22/2011 10:08:30 AM

TEL AVIV, Israel--(BUSINESS WIRE)--RedHill Biopharma Ltd. (TASE: RDHL), an emerging Israeli biopharmaceutical company focusing primarily on development and acquisition of late clinical-stage new formulations of existing drugs, announced the acquisition of an exclusive license from the University of Central Florida Research Foundation, Inc. (UCF) to a patent-protected diagnostic test for the detection of the MAP bacterium (Mycobacterium avium paratuberculosis). MAP is estimated to be found in 40%-50% of patients who suffer from Crohn’s disease - an inflammatory disorder of the gastrointestinal tract, affecting approximately 700,000 patients in the US alone, with currently no available cure.